文献速递肾小球疾病遗传性与小管间质肾病

人群测序数据库中预测致病性COL4A3-COL4A5变异频率及对Alport综合征的启示

Prevalence Estimates of Predicted Pathogenic COL4A3-COL4A5 Variants in a Population Sequencing Database and Their Implications for Alport Syndrome.
PubMed 文献 · J Am Soc Nephrol · 2021-06-18

本研究利用基于ACMG/AMP标准的过滤流程,在无已知肾脏疾病的人群测序数据库中鉴定预测致病性COL4A3-COL4A5变异,并计算其人群频率。结果显示,预测致病性COL4A5变异至少见于1/2320个体,而预测致病性杂合COL4A3/COL4A4变异影响1/106人群。这些频率可为Alport综合征的患病率提供参考,但需根据变异的外显率等因素进行调整。

要点

  • 预测致病性COL4A5变异在人群中的频率至少为1/2320。
  • 预测致病性杂合COL4A3/COL4A4变异影响1/106人群,与薄基底膜肾病一致。
  • 预测致病性复合杂合变异频率为1/88,866,双基因变异至少为1/44,793。

核心结论

  • 预测致病性COL4A3-COL4A5变异的人群频率可为Alport综合征患病率提供参考,但需根据变异外显率、已诊断疾病可能性及非甘氨酸替换进行调整。

研究设计与样本

  • 研究在无已知肾脏疾病的人群测序数据库中,使用基于ACMG/AMP标准的过滤步骤鉴定预测致病性COL4A3-COL4A5变异,并按平均测序等位基因数计算人群频率。

主要发现

  • 导致1位甘氨酸替换的COL4A3-COL4A5变异被证实与血尿相关(每个变异P<0.001)。
  • 预测致病性COL4A5变异至少见于1/2320个体;在欧洲人中p.(Gly624Asp)占变异近一半(16/33,48%)。
  • 大多数COL4A5变异(54/59,92%)具有可能减轻临床效应的生化特征。
  • 预测致病性杂合COL4A3和COL4A4变异影响1/106人群,与正常供肾活检标本中薄基底膜肾病的发现一致。
  • 预测致病性复合杂合变异发生于1/88,866个体,双基因变异至少见于1/44,793个体。

局限性

  • 疾病外显率可能取决于其他遗传和环境因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The reported prevalence of Alport syndrome varies from one in 5000 to one in 53,000 individuals. This study estimated the frequencies of predicted pathogenic COL4A3-COL4A5 variants in sequencing databases of populations without known kidney disease. METHODS: Predicted pathogenic variants were identified using filtering steps based on the ACMG/AMP criteria, which considered collagen IV α3-α5 position 1 Gly to be critical domains. The population frequencies of predicted pathogenic COL4A3-COL4A5 variants were then determined per mean number of sequenced alleles. Population frequencies for compound heterozygous and digenic combinations were calculated from the results for heterozygous variants. RESULTS: COL4A3-COL4A5 variants resulting in position 1 Gly substitutions were confirmed to be associated with hematuria (for each, P<0.001). Predicted pathogenic COL4A5 variants were found in at least one in 2320 individuals. p.(Gly624Asp) represented nearly half (16 of 33, 48%) of the variants in Europeans. Most COL4A5 variants (54 of 59, 92%) had a biochemical feature that potentially mitigated the clinical effect. The predicted pathogenic heterozygous COL4A3 and COL4A4 variants affected one in 106 of the population, consistent with the finding of thin basement membrane nephropathy in normal donor kidney biopsy specimens. Predicted pathogenic compound heterozygous variants occurred in one in 88,866 individuals, and digenic variants in at least one in 44,793. CONCLUSIONS: The population frequencies for Alport syndrome are suggested by the frequencies of predicted pathogenic COL4A3-COL4A5 variants, but must be adjusted for the disease penetrance of individual variants and for the likelihood of already diagnosed disease and non-Gly substitutions. Disease penetrance may depend on other genetic and environmental factors.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Gibson J, Fieldhouse R, Chan MMY, et al. Prevalence Estimates of Predicted Pathogenic COL4A3-COL4A5 Variants in a Population Sequencing Database and Their Implications for Alport Syndrome. J Am Soc Nephrol. 2021. PMID: 34400539. doi:10.1681/ASN.2020071065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。